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Abstract
Multiple studies have investigated global DNA methylation profiles and gene-specific DNA methylation in blood-
based DNA to develop powerful screening markers for cancer. This systematic review summarizes the current
evidence on methylation studies that investigated methylation level of blood-derived DNA of breast cancer (BC)
patients in comparison to healthy controls by conducting a systematic literature review in PubMed and Web of
Science. Essential results, such as methylation levels of BC cases and healthy controls, p values, and odds ratios,
were extracted from these studies by two investigators independently. Overall, 45 publications met the inclusion
criteria for this review. DNA from whole blood, as well as cell-free DNA (cfDNA) from serum or plasma, was used in
these studies. The most common method used for measuring global DNA methylation was the investigation of
repetitive elements as surrogates and the application of array-based genome-wide methylation analysis. For
measuring gene-specific methylation level, methylation-specific PCR and pyrosequencing were the most frequently
used methods. Epigenome-wide blood DNA hypomethylation in BC patients were reported in several studies;
however, the evidence is still not conclusive. The most frequently investigated gene in whole blood was BRCA1,
which was found more frequently methylated in patients compared to controls. RASSF1A was the most widely
investigated gene in cfDNA of serum or plasma, which was also found more frequently methylated in patients
compared to controls. Several of the eligible studies reported the associations of global hypomethylation and
increased BC risk. Studies investigated associations between gene-specific methylation and BC risk, while got
heterogeneous results. But two studies reported that hypermethylation of ATM gene was associated with increased
BC risk, which suggest the potential use of this gene for BC risk stratification. Overall, our review suggests the
possibility of using blood-based DNA methylation marker as promising marker for BC risk stratification, as several
studies found associations between certain methylation level in blood and BC risk. However, so far, the evidence is
still quite limited. Optimal markers are yet to be developed and promising results needed to be validated in
prospective study cohorts and tested in large screening populations.
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Background
Breast cancer (BC) is the most common malignancy
among women worldwide [1, 2]. The prognosis of this
disease mainly depends on its early detection, which
currently to a major part relies on mammography. Early
detection of this disease can also be facilitated by new
diagnostic biomarkers. The current Food and Drug
Administration (FDA)-approved blood-based biomarkers
for BC, such as CA15-3 and CA27-29, are solely
recommended for the monitoring of disease relapse and
treatment efficacy, rather than diagnosis [3, 4]. Specific
gene mutation tests, such as BRCA1/2 mutation analysis,
are currently only used for screening of hereditary BC
cases, which constitute only about 5–10% of total BC
cases [5, 6]. For women at normal risk of developing BC,
many national organizations recommend screening
mammography for older women. In the USA, screening
mammography is recommended every 2 years for
women at age between 50 and 74 [7]. However, the
present screening method is criticized for both low
sensitivity [8] and disadvantages due to over-diagnosis
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[9, 10]. Thus, alternative approaches for BC detection or
risk stratification are clearly needed.
Both global hypomethylation and silencing of tumor
suppressor genes through promoter hypermethylation
can come along with tumor development, and both have
been recognized as common hallmarks of many cancers
[11]. Similar alterations can also be measured in blood-
derived DNA, which suggests the possibility of blood-
based DNA methylation markers to serve as new
screening markers or markers for risk stratification
[12, 13]. To date, a considerable number of studies
on DNA methylation in cancer have used DNA ob-
tained from blood (whole blood or white blood cells)
or cell-free DNA (cfDNA) isolated from serum or plasma,
with the assessment of differences in methylation levels
between BC patients and cancer-free healthy controls, to
identify methylation markers [14–22]. A substantial num-
ber of studies concluded that BC patients and healthy
controls exhibit differential DNA methylation patterns in
peripheral blood. However, numerous further studies have
reported controversial findings, and clear evidence is still
lacking whether DNA methylation changes could serve as
biomarker for BC diagnosis or risk stratification.
The aim of this review is to summarize the current
evidence on DNA methylation-associated biomarkers for
BC risk evaluation or early detection, by performing a
comprehensive systematic review of published DNA
methylation studies in blood-derived DNA of BC pa-
tients in comparison to healthy controls. From each eli-
gible study, we extracted essential information, such as
age of study subjects, sample size, applied methylation
detection methods, methylation levels of patients and
healthy controls, p values for methylation differences,
and odds ratios (ORs), in order to gain insights into
the currently accumulated evidence regarding the use
of DNA methylation markers for potential future
screening tests.
Methods
Search strategy
A systematic literature search was performed to identify
studies assessing DNA methylation changes in blood as
biomarkers for risk or early detection of BC. PubMed
and ISI Web of Knowledge were searched for eligible
articles until 31 January 2016. The following combin-
ation of keywords was used: [breast] (and) [cancer (or)
neoplasm (or) carcinoma (or) adenoma (or) malignancy
(or) adenoma] (and) [DNA methylation (or) methylated
(or) hypermethylation (or) hypomethylation] (and) [risk
(or) detection (or) diagnosis] (and) [serum (or) blood
(or) plasma (or) white blood cell]. The literature search
was limited to studies focusing on humans and pub-
lished in English.
Eligibility criteria
Duplicate articles were removed upon combining the re-
trieved publications from the two databases. A first
round of selection was conducted by reviewing the titles
and abstracts. Only full-text reports of original studies
were included, thus meeting abstracts, reviews, and edi-
torials were excluded. Articles not focusing on DNA
methylation changes in blood in the context of BC de-
tection/diagnosis/risk prediction were excluded, includ-
ing studies that analyzed (1) DNA methylation markers
in tissue samples, (2) DNA methylation as prognostic
markers of BC or predictive markers for BC treatment
efficacy, and (3) DNA isolated from collected CTC cells.
After the first round examination, we conducted a
full-text review for the remaining articles. In addition,
studies that did not include healthy female controls, for
example, only with benign breast disease patients, were
not considered. Studies were also excluded if the infor-
mation regarding methylation levels of BC cases and
healthy controls or ORs were not reported or could not
be extracted from published data, for example, studies
that solely presented results by heatmaps or reported
the methylation levels of a combination of specific loci/
genes. Cross-referencing was used as a possible source
for identifying studies related to the present topic.
Data extraction and statistical analysis
Eligible studies were included in the data extraction
procedure, which was conducted independently by two
investigators (Q. Tang and J. Cheng) with a standardized
data extraction form. The following variables were
extracted: first author, publication year, study design, age
of study subjects, DNA source (whole blood, serum, or
plasma), DNA methylation detection method, the type
of measured DNA methylation (global or gene/locus
specific), and essential results (methylation levels of
cases and controls, ORs, p values). Any disagreement
was resolved by further review and discussion among
the coauthors. In case methylation levels were not expli-
citly reported, the information was extracted from avail-
able tables and figures to the possible extent. If not
presented in the articles, p values for methylation differ-
ences between BC cases and healthy controls were
calculated by Fisher’s exact test. Reporting of data
follows the PRISMA statements [23].
Results
Literature overview
The process of the systematic literature search is dis-
played in Fig. 1a. Briefly, the primary search in PubMed
and Web of knowledge identified 945 articles, of which
206 were duplicate articles. After excluding non-eligible
articles (see Fig. 1a and Additional file 1: Supplementary
materials), 45 articles could be included in this review,
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including 26 articles used DNA isolated from whole
blood [14–21, 24–41], two articles used DNA isolated
from both whole blood and plasma [42, 43], six articles
used DNA isolated from plasma [44–49], and 11 articles
used DNA isolated from serum [50–60] (Table 1). For
the studies that used serum or plasma as DNA source,
four of them used two centrifugation steps to get serum
or plasma [42, 45, 47, 48] and the rest used one centrifu-
gation step or sample processing procedures are not
available (Table 1). The included articles were published
between 2004 and 2015.
Among all eligible studies, only 11 studies investigated
global DNA methylation. This was always done in DNA
isolated from whole blood (Table 1). The majority of
studies measured gene- or locus-specific DNA methyla-
tion levels, in DNA isolated either from whole blood or
in cfDNA isolated from serum or plasma (Table 1). To get
a better overview of global DNA methylation changes, as
well as the differentially methylated genes between BC
patients and healthy controls, we summarize these studies
separately, as shown in Fig. 1b.
Global DNA methylation in peripheral blood of BC cases
and controls
As shown in Table 2, a total of 15 studies from 11 litera-
tures evaluated global DNA methylation levels in whole
blood by different strategies. These included using mean
methylation intensities of all Infinium HumanMethyla-
tion450K (450 K) probes (β value) as global DNA
methylation levels, measuring the percentage of methyl-
ated DNA by luminometric methylation assay (LUMA)
and the concentration of 5-methyldeoxycytosine (5-
mdC) by liquid chromatography-mass spectrometry
(LC-MS) or measuring the methylation of repetitive
DNA elements (i.e., LINE-1, Alu, or Sat2) by pyrose-
quencing or the MethyLight assay as surrogates of global
DNA methylation levels. Among them, four nested
case–control studies [17–19, 38] used prospectively
collected samples of BC cases and healthy controls,
while the remaining studies used samples collected at
diagnosis or shortly after diagnosis and healthy controls
[17, 26, 27, 29, 31–33, 36]. Case number of these studies
was between relative large (over 100 subjects for each
group), except the studies by Kitkumthorn N et al. (with
36 cases) [33] and Cho YH et al. (with 40 cases and 40
controls) [27]. Cases and controls used in these 14 stud-
ies were number- and age-matched.
As shown in Table 2, studies of van Veldhoven and
Severi reported epigenome-wide hypomethylation of
blood DNA in BC patients compared to controls, even
that van Veldhoven et al. [18] observed lower methyla-
tion in BC cases in one of their study cohorts, but not in
Fig. 1 a Flow diagram of the literature search process (search until 30.01.2016) and b summarize strategy of the review
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Table 1 Characteristics summary of the 45 eligible studies
Number First author Year Country DNA source Sample treatment Measurement Methylation
levels
available
Odds ratio
estimation
available
1 Widschwendter M 2008 Germany Blood – Gene-specific methylation Yes Yes
2 Snell C 2008 Australia Blood – Gene-specific methylation Yes No
3 Ito Y 2008 UK Blood – Gene-specific methylation Yes Yes
4 Flanagan. JM 2009 UK Blood – Gene-specific methylation Yes Yes
5 Choi JY 2009 USA Blood – Global DNA methylation Yes Yes
6 Cho YH 2010 Turkey Blood – Both global DNA methylation
and gene-specific methylation
Yes No
7 Hoffman AE 2010 Connecticut Blood – Gene-specific methylation No Yes
8 Wong EM 2011 Australia Blood – Gene-specific methylation Yes Yes
9 Iwamoto T 2011 Japan Blood – Gene-specific methylation Yes Yes
10 Brennan K 2012 Australia, New
Zealand, UK,
and Europe
Blood – Both global DNA methylation
and gene-specific methylation
Yes Yes
11 Xu X 2012 USA Blood – Global DNA methylation Yes Yes
12 Bosviel R 2012 France Blood – Gene-specific methylation Yes No
13 Wu HC 2012 USA Blood – Global DNA methylation Yes Yes
14 Delgado-Cruzata L 2012 USA Blood – Global DNA methylation Yes Yes
15 Kitkumthorn N 2012 Thailand Blood – Global DNA methylation Yes No
16 Hajikhan Mirzaei M 2012 Iran Blood – Gene-specific methylation Yes No
17 Askari M 2013 India Blood – Gene-specific methylation Yes Yes
18 Severi G 2014 Australia Blood – Global DNA methylation Yes Yes
19 Yang RX 2014 Germany Blood – Gene-specific methylation Yes Yes
20 Kuchiba A 2014 Japan Blood – Global DNA methylation Yes Yes
21 Gupta S 2014 Poland Blood – Gene-specific methylation Yes Yes
22 DeRoo LA 2014 USA Blood – Global DNA methylation No Yes
23 van Veldhoven K 2015 Italy Blood – Global DNA methylation Yes Yes
24 Cho YH 2015 USA Blood – Gene-specific methylation Yes Yes
25 Yari K 2015 Iran Blood – Gene-specific methylation Yes No
26 Harrison K 2015 Europe Blood – Gene-specific methylation Yes Yes
27 Zmetakova I 2013 Slovakia Blood and plasma 1000g for 10
min + 1000g for
10 min
Gene-specific methylation Yes No
28 Enders KN 2014 China Blood and plasma na Gene-specific methylation Yes No
29 Hoque MO 2006 Senegal Plasma 2200 rpm for
10–15 min
Gene-specific methylation Yes No
30 Papadopoulou E 2006 Greece Plasma 2000 rpm for 10
min + 2000 rpm
for 10 min
Gene-specific methylation Yes No
31 Yazici H 2009 USA Plasma na Gene-specific methylation Yes No
32 Radpour R 2011 Switzerland Plasma 16,006g for 10
min + full speed
10 min
Gene-specific methylation Yes No
33 Enders KO Ng 2011 China Plasma 1600g for 10
min + 16,000g
for 10 min
Gene-specific methylation Yes No
34 Chimonidou M 2013 Greece Plasma 2000g for 10 min Gene-specific methylation Yes No
35 Dulaimi E 2004 Pennsylvania Serum na Gene-specific methylation Yes No
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another two study cohorts. Three studies [29, 32, 36]
measured the global methylation content by LUMA
assay but obtained heterogeneous results. Specifically,
Kuchiba et al. [36] observed an increased global blood
DNA methylation in BC patients, while Xu et al. [29] re-
ported a decrease and Delgado-Cruzata et al. [32] found
no significant methylation differences between BC cases
and controls. Choi JY et al. [26] observed significant
lower level of 5-mdC in patients compared to con-
trols. Interestingly, nine studies from seven articles
[17, 26, 27, 29, 31, 33, 38] evaluated the methylation
level of LINE-1 repeats with different detection
methods, but almost all of them reported that there
were no significant difference in LINE-1 methylation
between BC cases and controls (Table 2). Studies investi-
gating Sat2 and Alu repetitive elements also revealed in-
consistent results (Table 2). Delgado-Cruzata L et al. [32]
observed significant higher [3H]-methyl acceptance (lower
DNA methylation) in patients than in controls.
Overall, the evidence of global DNA hypo- or hyper-
methylation in blood DNA of BC cases is so far limited
and not conclusive. As shown in Table 2, less than half
of these studies reported significant global hypomethyla-
tion in blood DNA of BC patients (Table 2) and the
overall methylation difference between BC cases and
controls are relative small (effect size varied from 0.013
to 0.25). This could be due to the complicated epigenetic
background of DNA isolated from whole blood as well
as the still high variability of quantitative DNA methy-
lation detection methods. In addition, the eligibility of
LINE-1 as surrogate for global DNA methylation level
might be limited, as nine studies observed no signifi-
cant difference of LINE-1 methylation between cases
and controls.
Some studies also investigated the associations be-
tween blood DNA methylation levels and BC risk by
quantile analysis, comparing the risk of women in the
highest quantile and that of women in the lowest quan-
tile (Fig. 2a) or vice versa (Fig. 2b). As shown in Fig. 2a,
Delgado-Cruzata and coauthors concluded that there
was no significant association between global DNA
methylation levels detected by LUMA assay and [3H]-
methyl acceptance assay and BC risk [32]. Wu HC et al.
[31] and DeRoo LA et al. [38] evaluated possible associa-
tions between the methylation level of repetitive ele-
ments (LINE-1, Alu, or Sat2) of blood DNA and BC
risk, but also with inconsistent results. Choi et al. used
the amounts of 5-mdC as surrogates for global DNA
methylation in blood and reported that women repre-
senting the lowest 5-mdC quantile had a higher risk of
BC (2.81, 95% CI 1.65–4.94), compared with women of
the highest quantile [26]. As shown in Fig. 2b, Xu et al.
[29] and Kuchiba et al. [36] revealed a positive associ-
ation between LUMA methylation level and BC risk.
Three large prospective studies were reported in two
articles. Here, the global DNA methylation was investi-
gated by 450K methylation arrays. Mean β values across
the whole genome were calculated and used as global
DNA methylation level [18, 19]. For women in the high-
est quantile compared to women in the lowest methyla-
tion quantile, the ORs (95% CI) were 0.34 (0.18–0.66)
(EPIC cohort) and 0.99 (0.56–1.76) (NOWAC cohort) in
the study of van Veldhoven et al. [18], and the ORs were
0.42 (0.20–0.90) in the study of Severi and coauthors
[19]. This suggests that hypomethylation in whole blood
might be associated with an increased risk of BC, even
the abovementioned results are inconclusive.
Overall, the association between global DNA methyla-
tion and BC risk is still unclear, as both positive associ-
ation and negative association were reported.
Gene-specific methylation in whole blood DNA of BC
cases and controls
Table 3 and Additional file 1: Table S1 list all the studies
that examined the methylation levels of specific gene loci
in whole blood DNA of BC cases and healthy controls.
All of these studies were case–control studies. The num-
ber of cases varied from only seven to 1021. The most
Table 1 Characteristics summary of the 45 eligible studies (Continued)
36 Martinez-Galan J 2008 Spain Serum 2000g for 10 min Gene-specific methylation Yes No
37 Van der Auwera I 2009 Belgium Serum 2000g for 10 min Gene-specific methylation Yes No
38 Chen Z 2009 China Serum 1000g for 10 min Gene-specific methylation Yes No
39 Zurita M 2010 Spain Serum 2000g for 10 min Gene-specific methylation Yes No
40 Ahmed IA 2010 Germany Serum 2000g for 10 min Gene-specific methylation Yes No
41 Brooks JD 2010 USA Serum na Gene-specific methylation Yes No
42 Kim JH 2010 Korea Serum na Gene-specific methylation Yes No
43 Kloten V 2013 Germany Serum 2000g for 10 min Gene-specific methylation Yes No
44 Swellam M 2015 Egypt Serum 1600g for 15 min Gene-specific methylation Yes No
45 Liu LM 2015 China Serum na Gene-specific methylation Yes No
na not available
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Table 2 Global DNA methylation in peripheral blood of breast cancer cases and healthy controls
Measurements Author, year [ref] Study design Assay (value) Case
no./control no.
Case age/control
age (y)a
Meth (case) Meth (control) p value Main findings
β value van Veldhoven K,
2015 [18]
Nested case–control 450 K (EPIC cohort)
(mean + SD)
162/162 54.4/54.2 53.00 ± 0.39 53.18 ± 0.35 1.82E−05 Epigenome-wide
hypomethylation
of DNA in samples
from EPIC cohort.450 K (NOWAC
cohort) (mean + SD)
168/168 55.4/55.4 54.02 ± 0.45 54.02 ± 0.41 0.79
WBGS (BGS cohort) (mean) 548/548 52/52 48.12 48.3 na
Severi G, 2014 [19] Nested case–control 450 K (mean + SD) 420/420 64/64 51.86 ± 1.00 51.95 ± 1.01 0.006 Epigenome-wide
hypomethylation
of DNA in BC patients.
LUMA Kuchiba A, 2014 [36] Case–control LUMA (% DNA meth) 384/384 54.1/53.9 68.9 ± 3.5 70.2 ± 3.4 <0.01 Global genomic
hypomethylation
in BC patients.
Xu X, 2012 [29] Case–control LUMA (%) 1055/1101 na/na 57.3 ± 15.7 52.4 ± 16.7 <0.0001 Global promoter
hypermethylation
in patients.
Delgado-Cruzata
L, 2012 [32]
Case–control LUMA (%) 263/321 49.5/48.0 67.1 ± 7.6 67.5 ± 7.3 >0.05 LUMA DNA methylation
levels were similar
between cases and
controls.
5-mdC Choi JY, 2009 [26] Case–control LC-MS (test set)
(mean)
19/18 35–75/35–75 3.98 4.33 0.001 Hypomethylation of
5-mdC in BC patients.
LC-MS (validation
set) (mean)
176/173 35–75/35–75 4.18 ± 0.34 4.38 ± 0.36 <0.001
LINE-1 Kitkumthorn N,
2012 [33]
Case–control COBRA (%) 36/144 50.28/48.67 40 42 >0.05 No significant differences
in LINE-1 methylation
between BC cases and
healthy controls.
Xu X, 2012 [29] Case–control Pyrosequencing
(mean)
1064/1100 na/na 78.8 78.8 0.94 As above.
Brennan K, 2012
[17]
Pyrosequencing
(mean
and IQR)
As above.
Case–control BGS cohort 241/242 54/54 79.0 (78.1–79.9) 79.0 (77.9–80.1) 0.96
Case–control EPIC cohort 232/263 52/52 75.2 (73.9–76.3) 75.1 (73.9–76.3) 0.89
Nested case–control KConFab cohort 153/218 50/60 76.6 (75.2–77.6) 76.0 (74.3–78.0) 0.2
Wu HC, 2012 [31] Case–control MethyLight (%) 265/333 49.5/48.0 107.4 ± 63.6 108.5 ± 59.1 >0.05 As above.
Pyrosequencing
(mean)
279/340 49.5/48.0 74.5 ± 3.0 74.5 ± 2.6 >0.05
Cho YH, 2010 [27] Case–control MethyLight (%) 40/40 50.8/48.3 70 78 >0.05 As above.
Choi JY, 2009 [26] Case–control 19/18 35–75/35–75 74.7 73.9 0.176 As above.
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Table 2 Global DNA methylation in peripheral blood of breast cancer cases and healthy controls (Continued)
Pyrosequencing
(mean)
Deroo LA, 2014
[38]b
Nested case–control Pyrosequencing 294/646 57.9/na na na na As above.
Sat2 Wu HC, 2012 [31] Case–control MethyLight (%) 266/333 49.5/48.0 41.3 ± 24.4 43.5 ± 32.9 >0.05 No significant differences
in Sat2 methylation
between BC cases and
healthy controls.
Cho YH, 2010 [27] Case–control MethyLight (%) 40/40 50.8/48.3 125 150 0.01 Hypomethylation of
Sat2 inpatients.
Alu Wu HC, 2012 [31] Case–control MethyLight (%) 266/334 49.5/48.0 95.5 ± 36.6 98.7 ± 51.5 >0.05 No significant differences
in Alu methylation
between BC cases and
healthy controls.
Cho YH, 2010 [27] Case–control MethyLight (%) 40/40 50.8/48.3 58 61 >0.05 As above.
[3H]-methyl Delgado-Cruzata
L, 2012 [32]
Case–control [3H]-Methyl
acceptance assay
233/295 49.6/48.2 97,111 ± 76,348 88,030 ± 70,841 <0.05 Global genomic
hypomethylation
in BC patients (more
[3H]-methyl acceptance).
The numbers in italic are extracted from boxplot or scatter plots
450K Infinium HumanMethylation 450K Beadchips, WGBS whole genome bisulfite sequencing, LUMA luminometric methylation assay, COBRA combined bisulfite restriction analysis, 5-mdC 5-methyldeoxycytosine, na
not available
aAge indicates mean age or range
bThe mean DNA methylation level of BC cases and controls is not available; the study only reported the results of the quartile analysis
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frequently used methods for detection of gene-specific
methylation levels were MethyLight and pyrosequencing.
BRCA1 was investigated in seven studies and thus the most
frequently investigated gene [16, 20, 24, 27, 30, 37, 39].
Importantly, all these studies reported a rather higher
frequency of methylated BRCA1 in BC cases than in
healthy controls, although the differences were only
statistically significant in four studies [16, 20, 24, 37].
ATM was investigated in two studies [15, 17], and
both of them observed hypermethylation of ATM in
BC patients. Methylation levels of IGF2 [25, 41],
CDH1 [39, 42], SYK [14, 42], RARB [27, 39], APC
[27, 42], and RASSF1A [27, 42] were found similar
between BC patients and controls in two or more studies.
Methylation of ESR [14, 42] and TIMP3 [14, 42] were also
determined in more than one study, while the methylation
differences of these genes between blood DNA of BC
cases and controls were not conclusive. Other genes
investigated in only one study were summarized in
Additional file 1: Table S1.
Figure 3 shows the associations of gene-specific
methylation in blood and BC risk. Yang et al. [21]
showed that reduced methylation levels of the HYAL2
gene were significantly associated with increased BC
risk. Specifically, women in the highest quartile of
HYAL2 methylation were reported to have a 41.47-fold
(cohort I) and a 132.98-fold (cohort II) increased BC
risk, compared with women in the lowest quartile
(Fig. 3a). Hypermethylation of ATM and increased BC
risk were observed in two studies [15, 17]. Here, the
lowest methylation quantile was used as reference
(Fig. 3b). Hoffman et al. observed a negative association
between CLOCK methylation and BC risk [28] (Fig. 3b).
Widschwendter et al. investigated methylation of a few
genes in a case–control study (n = 1083) and found that
decreased DNA methylation in NUP155 (I), ZNF217 (II),
Fig. 2 Associations of global DNA methylation in blood and BC risk. a Studies used the highest methylation quantile as reference. b Studies used
the lowest methylation quantile as reference
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Table 3 Gene-specific methylation in peripheral blood DNA in breast cancer cases and controls investigated in more than one study
Gene Author, year [ref]a Assay (value) Case
no./control no.
Case age/control
age (y)b
Meth (case) Meth (control) p value Main findings
BRCA1 Cho YH, 2015 [39] MethyLight (%) 1021/1036 na/na 12 10 >0.05 Higher frequency of methylated
BRCA1 in BC patients was observed
in all six studies.Gupta S, 2014 [37] MS-HRM (%) 66/36 48.8/56.1 22.7 5.6 0.03
Bosviel R, 2012 [30] QMSP (%) 902/990 47.1/45.9 47.1 (46.1–48.1) 45.9 (45.0–46.8) 0.08
Wong EM, 2011 [20] MS-HRM (%) 255/169 <40/<40 10.9 3.6 0.004
Iwamoto T, 2011 [16] MSP (%) 200/200 50/50 21.5 13.5 0.045
Cho YH, 2010 [27] MethyLight (%) 40/40 50.8/48.3 8 5 >0.05
Snell C, 2008 [24] MethyLight (%) 7/7 35–51/35–51 42.9 14.3 <0.05
ATM Brennan K, 2012 [17] Pyrosequencing ATM (mvp2a) Hypermethylation of ATM (intragenic
repetitive element) in BC patients was
observed in two studies.BGS cohort (mean and IQR) 249/248 54/54 76.8 (70.9–82.7) 76.4 (70.2–80.2) 0.02
EPIC cohort (mean and IQR) 235/283 52/52 75.7 (70.0–80.8) 76.1 (70.5–80.6) 0.4
KConFab cohort (mean and IQR) 156/210 50/60 81.8 (75.8–86.5) 76.9 (71.6–81.5) 4.87 × 10−6
Pyrosequencing ATM (mvp2b)
BGS cohort (mean and IQR) 248/234 54/54 91.4 (85.6–95.0) 91.0 (87.0–94.8) 0.61
EPIC cohort (mean and IQR) 240/287 52/52 92.3 (88.3–95.7) 92.2 (87.3–95.2) 0.36
KConFab cohort (mean and IQR) 162/208 50/60 92.3 (82.4–96.5) 92.6 (87.2–96.3) 0.24
Flanagan JM, 2009 [15] Pyrosequencing (mean and IQR) 190/190 62.8/62.8 91.4 (72.8–98.4) 89.8 (53.0–98.0) 0.002
IGF2 Harrison K, 2015 [41] Pyrosequencing (mean ± SD) 189/363 56/56 48.94 ± 5.61 48.15 ± 5.77 0.123 Two studies reported no significant
differences in methylation of IGF2
between BC cases and healthy controls.Ito Y, 2008 [25] Pyrosequencing
(% of loss of methylation)
EPIC-Norfolk cohort 228/460 60.5/60.3 6.6 6.3 0.91
ABC cohort 338/84 52.6/43.2 5.6 7.1 0.65
CDH1 Cho YH, 2015 [39] MethyLight (%) 1021/1036 na/na 58 66 >0.05 Three studies observed no significant
differences in methylation of CDH1
between BC cases and controls.Zmetakova I, 2013 [42] Pyrosequencing (mean ± SD) 34/50 41–90/20–78 9.64 ± 2.10 9.02 ± 1.60 0.698
Cho YH, 2010 [27] MethyLight (%) 40/40 50.8/48.3 8 8 >0.05
ESR1 Zmetakova I, 2013 [42] Pyrosequencing (mean ± SD) 34/50 41–90/20–78 4.09 ± 1.44 3.22 ± 0.86 0.026 Zmetakova I et al. reported higher
methylation of ESR1 in patients, while
Widschwendter. M et al. observed no
significant difference.
Widschwendter M, 2008 [14] MethyLight (%) 320/676 50–74/50–74 12.2 13.5 0.645
SYK Zmetakova I, 2013 [42] Pyrosequencing (mean ± SD) 34/50 41–90/20–78 1.15 ± 0.44 1.06 ± 0.24 0.638 Both studies observed no significant
differences in methylation of SYK
between BC cases and controls.Widschwendter M, 2008 [14] MethyLight (%) 320/676 50–74/50–74 2.2 2.4 0.889
TIMP3 Zmetakova I, 2013 [42] Pyrosequencing 34/50 41–90/20–78 3.65 ± 2.55 2.50 ± 0.81 0.036 Zmetakova I et al. reported higher
methylation of TIMP3 in patients, while
Widschwendter. M et al. observed no
significant difference.
Widschwendter M, 2008 [14] MethyLight (%) 320/676 50–74/50–74 12.5 14.2 0.511
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Table 3 Gene-specific methylation in peripheral blood DNA in breast cancer cases and controls investigated in more than one study (Continued)
RARB Cho YH, 2015 [39] MethyLight (%) 1021/1036 na/na 33 39 >0.05 Two studies reported no significant
differences in methylation of RARB
between BC cases and healthy controls.Cho YH, 2010 [27] MethyLight (%) 40/40 50.8/48.3 10 10 >0.05
APC Zmetakova I, 2013 [42] Pyrosequencing (mean ± SD) 34/50 41–90/20–78 1.68 ± 1.04 1.28 ± 0.57 0.082 Two studies reported no significant
differences in methylation of APC
between BC cases and healthy controls.Cho YH, 2010 [27] MethyLight (%) 40/40 50.8/48.3 0 0 >0.05
RASSF1A Zmetakova I, 2013 [42] Pyrosequencing (mean ± SD) 34/50 41–90/20–78 1.00 ± 0.00 1.04 ± 0.28 0.475 Two studies reported no significant
differences in methylation of RASSF1A
between BC cases and healthy controls.Cho YH, 2010 [27] MethyLight (%) 40/40 50.8/48.3 8 3 >0.05
na not available
aAll studies were case–control study
bAge indicates mean age or range
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PTGS2, TITF1, NEUROD1, and SFRP1 are associated
with increased BC risk [14] (Fig. 3c). Hypermethylation
of BRCA1 promoter was associated with increased BC
risk, which was confirmed in two independent studies
[16, 37] (Fig. 3c).
Gene-specific methylation in cfDNA from serum or
plasma of BC cases and controls
Table 4 summarizes all studies that investigated methyla-
tion differences of specific genes in serum or plasma
DNA of BC cases and healthy controls. Studies con-
ducted by Yazici et al. [46] and Brooks et al. [56] were
nested case–control studies and the remaining studies
were all case–control studies. Generally, the sample sizes
were rather low. Case number varied from 4 to 250. All
eligible studies using serum or plasma DNA investigated
DNA methylation levels at specific loci, rather than
global DNA methylation levels. Further, so far no
epigenome-wide study has been performed on cfDNA.
This can be explained by the technical difficulties due to
the specific characteristics, such as strongly fragmented
DNA and reduced DNA integrity especially in cancer
cases [61]), and limited amounts of cfDNA that can be
isolated from serum or plasma [62–64], and also to
uncertainties regarding its origins [65]. The most
common method used to measure the methylation
levels of specific genes in serum or plasma cfDNA
was methylation-specific PCR (MSP) (Table 4 and
Additional file 1: Table S2).
Most of these studies investigated tumor suppressor
genes and frequently reported the hypermethylation of
these genes in BC patients (Table 4 and Additional file 1:
Table S2). With ten studies, RASSF1A was the most fre-
quently evaluated gene and eight of them reported higher
frequency of methylated RASSF1A in BC patients com-
pared to controls [42, 44–46, 50, 52, 55–58]. APC has been
investigated in seven studies [42, 44, 47, 50, 52, 56, 59].
Among them, five studies reported higher frequency of
methylated APC in plasma/serum DNA of BC patients.
Higher frequency of methylated RARB (also known as
RARβ2) was observed in four studies [44, 56, 57, 59].
Methylation levels of ESR1 [42, 51, 52, 54], GSTP1
[44, 47, 56], and TIMP3 [42, 47] were each investi-
gated in two or more studies, but each gene yielded
with inconclusive results. Hypermethylation of SFN (also
known as stratifin or 14-3-3-σ) [51, 54], BRCA1 [47, 60],
CST6 [47, 49], and DAPK [49, 50] were confirmed in two
independent studies, respectively (Table 4). Brooks J.D. et
al. [56] reported no significant differences in the methyla-
tion of all four genes (RASSF1A, GSTP1, APC, and RARB)
investigated between BC cases and controls. It is worth to
point out that the DNA amounts used in this study were
Fig. 3 Associations of gene-specific methylation in blood and BC risk. a Studies used the highest methylation quantile as reference. b Studies
used the lowest methylation quantile as reference. c Studies used methylation of controls as reference. aThe upper limit of 95% CI of the study
of Gupta was over ten. bWidschwendter M and coauthors investigated the genes from ZNF217 to TIMP3
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Table 4 Gene-specific methylation in serum or plasma DNA in breast cancer cases and controls investigated in more than one study
Gene Author, year [ref] Sample Assay (value) Case
no./control no.
Case age/control
age (y)b
Meth (case) Meth (control) p value Main findings
RASSF1A Kloten V, 2013 [58] Serum MS-PCR (%) 136/135 33–86/33–86 47.1 25.9 0.004 Higher frequency of methylated RASSF1A
was observed in eight studies. Studies by
Zmetakova I et al. and Brooks JD et al.
reported no significant differences in
methylation of RASSF1A between cases
and controls
Zmetakova I, 2013 [42] Plasma Pyrosequencing (mean ± SD) 34/50 41–90/20–78 2.85 ± 3.13 4.02 ± 6.62 0.404
Ahmed IA, 2010 [55] Serum MSP (%) 26/12 35–73/35–73 69 <10 –
Brooks JD, 2010 [56]d Serum QMSP (%) 50/99 52/51.8 22 17.2 >0.05
Kim JH, 2010 [57] Serum QMSP (%) 119/125 51/51 32.8 4.8 0.004
Yazici H, 2009 [46]d Plasma MSP (%) 61/39 na/na 18 5 –
Hoque M, 2006 [44] Plasma QMSP (%) 47/38 44.9/37.3 32 5 0.002
Van der Auwera I, 2009 [52] Serum QMSP (%) 79/19 62/39 35 0 0.002
Papadopoulou E, 2006 [45] Plasma Methylight (%) 50/14 na/na 26 0 <0.05
Dulaimi E, 2004 [50] Serum MSP (%) 34/20 57.4/57.4 56 0 <0.05c
APC Swellam M, 2015 [59] Serum MS-PCR (%) 121/66 43/40 93.4 0 <0.0001 Five out of these seven studies reported
higher frequency of methylated APC in
BC patients. Studies by Zmetakova I et al.
and Brooks JD et al. reported no significant
differences in methylation of APC between
cases and controls.
Zmetakova I, 2013 [42] Plasma Pyrosequencing (mean ± SD) 34/50 41–90/20–78 4.41 ± 7.81 2.53 ± 1.56 0.06
Radpour R, 2011 [47] Plasma EpiTyper assay (mean) 36/30 67/na 0.39b 0.19b <0.0001
Brooks JD, 2010 [56]d Serum QMSP (%) 49/96 52/51.8 2 4.2 >0.05
Hoque M, 2006 [44] Plasma QMSP (%) 47/38 44.9/37.3 17 0 0.008
Van der Auwera I, 2009 [52] Serum QMSP (%) 79/19 62/39 29 5 0.03
Dulaimi E, 2004 [50] Serum MSP (%) 34/20 57.4/57.4 29 0 <0.05c
ESR1 Zmetakova I, 2013 [42] Plasma Pyrosequencing (mean ± SD) 34/50 41–90/20–78 4.18 ± 4.07 5.24 ± 4.33 0.338 Only one study (Matinez-Galan, J) reported
higher methylation levels of ESR1 in BC
patients. Others observed no significant
methylation differences.
Zurita M, 2010 [54] Serum QMSP (%) 77/34 na/na 0.005b 0.085b >0.05
Van der Auwera I, 2009 [52] Serum QMSP (%) 79/19 62/39 20 10.5 0.33
Martinez-Galan J, 2008 [51] Serum MSP (%) 106/74 58/42 0.11b 0.02b 0.011
RARB Swellam M, 2015 [59] Serum MS-PCR (%) 121/66 43/40 95.9 0 <0.0001 Higher frequency of methylated RARB
was observed except the study conducted
by Brooks JD et al.Brooks JD, 2010 [56]
d Serum QMSP (%) 45/88 52/51.8 6.7 1.1 >0.05
Kim JH, 2010 [57] Serum QMSP (%) 119/125 51/51 86.6 6.4 <0.001
Hoque M, 2006 [44] Plasma QMSP (%) 47/38 44.9/37.3 26 8 0.03
GSTP1 Radpour R, 2011 [47] Plasma EpiTyper assay (mean) 36/30 67/na 0.52b 0.39b 0.003 Two studies reported higher methylation
level (Radpour R et al., 2011) or frequency
(Hoque M et al., 2006) of GSTP1 in BC
patients. Study by Brooks.J.D observed no
significant differences.
Brooks JD, 2010 [56]d Serum QMSP (%) 50/99 52/51.8 4 7.1 >0.05
Hoque M, 2006 [44] Plasma QMSP (%) 47/38 44.9/37.3 26 0 0.0008
SFN Zurita M, 2010 [54] Serum QMSP (%) 77/34 na/na 0.002b 0.1b <0.001 Both studies reported higher methlyation
of SFN in BC patients.
Martinez-Galan J, 2008 [51] Serum MSP (%) 106/74 58/42 0.20b 0.075b 0.0047
BRCA1 Liu LM, 2015 [60] Serum Bisulfite sequencing
PCR and MS-HRM (%)
36a/30a na/na 10 1.7 <0.05 Both studies reported higher methlyation
of BRCA1 in BC patients
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Table 4 Gene-specific methylation in serum or plasma DNA in breast cancer cases and controls investigated in more than one study (Continued)
Radpour R, 2011 [47] Plasma EpiTyper assay 36/30 67/na 0.58b 0.30b <0.0001
CST6 Chimonidou M, 2013 [49] Plasma MSP (%) 73/37 na/na 16.4 0 ChimonidouM et al. reported that CST6
promoter is highly methylated in cfDNA of
breast cancer patients, but not in healthy
individuals. Radpour R et al. observed higher
methlytion level of CST6 in BC patients.
Radpour R, 2011 [47] Plasma EpiTyper assay (mean) 36/30 67/na 0.62b 0.42b <0.002
DAPK Ahmed IA, 2010 [55] Serum MSP (%) 26/12 35–73/35–73 88 <10% <0.05 Higher frequency of methylated DAPK in
patients was observed in both studies.
Dulaimi E, 2004 [50] Serum MSP 34/20 57.4/57.4 35 0 <0.05c
TIMP3 Zmetakova I, 2013 [42] Plasma Pyrosequencing (mean ± SD) 34/50 41–90/20–78 3.97 ± 8.43 3.92 ± 4.54 0.697 Zmetakova I et al. reported no significant
difference in methylation of TIMP3 between
patients and healthy controls. Radpour
R et al. observed higher methylation level
of TIMP3 in BC patients.
Radpour R, 2011 [47] Plasma EpiTyper assay 36/30 67/na 0.60b 0.50b <0.0001
MSP methylation-specific PCR, QMSP quantitative methylation-specific PCR, MS-HRM methylation-sensitive high-resolution melting, na not available
aAge indicates mean age or range
bData was extracted from scatter plots or boxplots in the article
cp values were calculated by Fisher’s exact test
dNested case–control study; the others are case–control study
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about five times less than the amount hypothetically re-
quired to achieve optimal sensitivity and non-specific
amplification might occur due to a high number of PCR
cycles (i.e., quantitative MSP (QMSP) was run for 50 cy-
cles), as the authors discussed in the article. The authors
observed lower frequency of methylation than expected
among cases and higher than expected among controls in
this study as compared to other studies (review in [66]),
which might be the reasons for the negative results. Other
genes, which were investigated in only one study, were
summarized in Additional file 1: Table S2.
Discussion
Our literature review identified 45 articles investigating
blood-based DNA methylation markers for BC detection
or risk evaluation, with DNA isolated from whole blood
or from serum or plasma. In this systematic review, we
summarized the differences in epigenome-wide DNA
methylation levels or gene-specific methylation that were
between BC patients and healthy females in all these
studies. In particular, several large nested or respective
case–control studies were conducted in recent years.
This could be partly attributed to the novel emerging
techniques, such as Infinium Humanmethylation 27K or
450K array or whole genome bisulfite sequencing
(WGBS), which are effective ways to screen for and
identify large numbers of methylation markers.
Even though whole blood DNA presents a mixture of
leucocytes subtypes, DNA methylation from whole
blood samples seems to be promising reservoir for in-
formative biomarkers for BC risk stratification. Two
nested case–control studies have concluded that such
genomic hypomethylation continuum can be evident at
blood DNA level and may identify high-risk women
before developing BC [18, 19]. Some retrospective case–
control studies also reported that cancer patients have
lower global methylation levels in blood DNA compared
to controls (Table 2). As blood DNA can be assessed
easily, its epigenetic effects on cancer propensity could
be repeatedly examined in specified time intervals.
Repetitive DNA sequences (e.g., LINE-1, Alu, and
Sat2) are all comparatively rich in CpG dinucleotides
and contain a large portion of total methylcytosine levels
in the genome [67, 68]. In this regard, some researchers
suggested that repetitive elements in blood DNA might be
surrogate for genomic hypomethylation. Studies of BC,
however, have yielded heterogeneous results (Table 2).
Choi et al. [26] found decreased methylation of 5-mdC in
blood DNA of women with BC compared to controls;
meanwhile, Wu HC et al. [31] and Cho et al. [27] found
decreased methylation of Sat2 in BC patients. Xu et al.
[29], however, found increased global methylation among
cases using the luminometric methylation assay. In the
study of Choi et al., LINE-1 methylation and %5-mdC
were not correlated, and only hypomethylation quantified
as %5-mdC level was significantly associated with BC risk
[26]. The inconsistencies between results in BC patients
and normal females probably arise from different detec-
tion targets, using different techniques and/or from differ-
ential distributions of clinical characteristics.
In the implementation and interpretation of studies
based on blood samples, a potential limitation deserving
particular attention is that differences in methylation
profiles might also reflect differences in the proportions
of the leukocyte subpopulations that make up the whole
blood [69, 70]. Hence, the majority of EWASs adjusted
their analysis for leucocyte distribution with the
algorithm of Houseman et al. [69]. Nevertheless, even if
BC-related methylation patterns were partly due to con-
founding by leucocyte distribution, they might still be
useful as biomarkers of BC.
Circulating cfDNA is defined as extracellular DNA
occurring in blood. Both plasma and serum are cell-free
blood specimens that were used for the determination of
cfDNA. Silencing of tumor suppressor genes by pro-
moter hypermethylation is known to be a frequent and
early event in carcinogenesis [11]. Further, changes in
methylation patterns observed in tumors are also detect-
able in cfDNA of women with BC and showed good
concordance [50, 71–74]. This makes the possibility of
using these alterations candidate markers for early
tumor detection. Among all the identified studies in our
review, the largest number of studies was found for
BRCA1 and RASSF1A, for which higher frequencies of
methylated BRCA1 and RASSF1A in BC patients than in
healthy females were reported rather consistently. Other
tumor suppressor genes, such as APC, RARB, GSTP1,
DAPK, and SFN were also found more frequently meth-
ylated in BC cases than in controls. Methylation-specific
PCR was the most frequently employed method in the
studies evaluating the methylation of specific genes in
whole blood and plasma/serum.
Circulating cfDNA, presumably shed from the original
primary tumor, can be retrieved and tested for genetic and
epigenetic alterations. However, so far, little is known
about the relationship between detection of epigenetic
abnormalities in primary BC tissue and detection of such
abnormalities in plasma or serum. In addition, the amount
of cfDNA is around 5–20 ng/ml in the circulation of a
normal individual [62, 75], which strongly depends on the
accurate sample processing [61]. This could be the main
obstacle in finding tumor-specific differences in sera/
plasma and the main reason of the lack of sensitivity of
the epigenetic biomarkers studied [42]. cfDNA may be re-
leased to the circulation via passive release as a result of
cellular apoptosis and necrosis and/or active secretion
from live cells. The cfDNA can comprise long fragments
or shorter fragments ranging from around 20 to 20 kb,
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depending on their mechanism of release into the circula-
tion [63, 64]. It has been shown by experiments on fetal
DNA in the maternal circulation that the half-life of free
DNA in blood is only around 16 min [76]. The limited
amount, intrinsic characteristics, and short half-life of
cell-free DNA could partly explain that for the markers
evaluated in more than one study, the methylation differ-
ences between cases and controls are not consistent and
sometimes varied greatly across studies. The discrepancy
probably could also arise from diverse study design, use of
different sources of DNA, and/or from differential distri-
butions of clinical characteristics.
Changes in DNA methylation profiles, both at overall
genomic level and specific loci, have been associated
with BC risk (Fig. 2 and Fig. 3). Among all the studies
included in the present review, in total, eight studies
measured overall WBC global DNA methylation and BC
risk (Fig. 2). Four of these studies [18, 19, 26, 38] have
found a significant elevated risk for BC between those in
the lowest quantile of global DNA methylation com-
pared to those in the highest methylation quantile. How-
ever, Kuchiba A et al. [36] and Xu X et al. [29] found a
positive association between LUMA methylation and
increased BC risk. The few studies investigating the
gene-specific methylation in blood DNA also sup-
ported the potential for gene-specific methylation as
biomarkers for risk (Fig. 3). However, research in this
field is still at an early stage. So far, the number of
studies that conducted epigenome-wide studies to de-
tect BC associated genes is very limited. More evi-
dence, including both genome-wide hypomethylation
level and gene-specific hypo- and hypermethylation
and BC risk, is still needed to collect.
BC is a highly heterogeneous disease. Many of the
established risk factors are linked to the development
of the disease. The highest risk factor for sporadic BC
is increasing age. The incidence of BC in women dou-
bles for every 10 years until menopause with a relative
risk of >10-fold [77]. Because promoter hypermethyla-
tion may be related to age, studies investigating a
potential diagnostic utility for methylated genes should
have a reasonable number of age-matched controls.
While some authors chose an age-matched control
group, others did not and the age difference between
cases and controls was often rather large. For example,
Zmetakova I et al. [42] compared BC patients with age
range between 41 and 90 years with healthy blood
donors of considerably younger age (range 20–78). The
control group of the study conducted by Ito Y et al.
[25] even had an average of 43.2, which is almost
10 years younger than the mean age of BC patients
(52.6) they included. Thus, the observed methylation
differences and associations between methylation
changes and BC risk might be confounded by age.
To our knowledge, this is the first review to systematic-
ally and comprehensively review and summarize results of
epidemiological studies on the association of DNA methy-
lation in blood with BC. In the interpretation of this re-
view, some limitations have to be considered. Although
two widely used databases were searched and cross-
referencing of identified articles was applied, we cannot
exclude having missed relevant studies. Furthermore,
studies were reported in a rather heterogeneous manner,
which limited possibilities of a standardized summary of
the results. Because of the heterogeneous nature of the in-
cluded studies and the fact that quite a few markers were
evaluated in single studies only, we did not conduct meta-
analyses and our tables only provide a narrative summary
of the reported methylation differences.
Conclusions
Our review suggests the possibility of using blood-based
methylation markers for risk stratification or the early de-
tection of BC, as a number of studies support an associ-
ation between methylation changes in blood and BC risk,
irrespective of full understanding of the pathophysio-
logical mechanisms. However, the evidence is still very
limited. Optimized marker panels are yet to be developed
and promising candidate markers needed to be validated
in prospective study cohorts and tested in large screening
populations by high quality studies. In addition, there is a
strong need for large, methodologically rigorous epi-
demiological studies to figure out the potential role of
methylation changes in blood in breast carcinogenesis and
their implications for detection. Especially, the investiga-
tion of methylation changes in cfDNA holds great prom-
ises. Here, optimization of methods for genome-wide
methylation analysis of small amounts of DNA is needed.
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